View More View Less
  • 1 Semmelweis University Institute of Medical Microbiology Nagyvárad tér 4 H-1089 Budapest Hungary
  • | 2 Semmelweis University Central Laboratory (Pest), Clinical Microbiological Diagnostic Laboratory Nagyvárad tér 4 H-1089 Budapest Hungary
  • | 3 State Health Center Department of Microbiology Róbert Károly krt. 44 H-1134 Budapest Hungary
  • | 4 State Health Center First Department of Medicine Róbert Károly krt. 44 H-1134 Budapest Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

The aim of the study was to investigate the biofilm-production of 60 Pseudomonas aeruginosa strains isolated from clinical samples and to examine the effect of different antimicrobials and their combinations with clarithromycin on biofilm-formation.The minimal inhibitory concentrations (MICs), minimal biofilm inhibitory concentrations (MBICs), and antibiotic synergy by calculating the fractional inhibitory concentration (FIC) index were determined for the following antibiotics: ceftazidime, cefepime, piperacillin/tazobactam, imipenem, meropenem, levofloxacin, ciprofloxacin, gentamicin, amikacin, tobramycin, netilmicin and clarithromycin.A total of 14 (23.3%) isolates out of 60 isolates of P. aeruginosa were biofilm positive. Cefepime, imipenem and meropenem had the lowest MIC90 values. Piperacillin/tazobactam and clarithromycin had the highest MIC90 values. Imipenem, meropenem, piperacillin/tazobactam and clarithromycin had the lowest MBIC90 values.For biofilm-forming P. aeruginosa strains 2-fold to 128-fold higher MBIC values than MIC values were obtained for ceftazidime, cefepime, imipenem, amikacin and netilmicin. The MBIC was 2-fold to 512-fold lower then the MIC values in the case of piperacillin/tazobactam, ciprofloxacin, levofloxacin and clarithromycin.Synergy was generally demonstrated for clarithromycin in combination with aminoglycosides, fluoroquinolones or ceftazidime. However, surprisingly it was found that combinations of clarithromycin with carbapenems or cefepime led to an antagonistic interaction: combination of clarithromycin with imipenem, meropenem or ertapenem showed antagonism in 37.5%, 50% and 62.5% of the strains tested whereas its combination with cefepime expressed antagonism in 75% of the strains, respectively. To the best of our knowledge no one has previously described this phenomenon so far.

  • Hoštacká, A., Čižnár, I., Slobodníková, L., Kotulová, D.: Clinical Pseudomonas aeruginosa: potential factors of pathogenicity and resistance to antimicrobials. Folia Microbiol. 51, 633–638 (2006).

    Kotulová D. , 'Clinical Pseudomonas aeruginosa: potential factors of pathogenicity and resistance to antimicrobials ' (2006 ) 51 Folia Microbiol. : 633 -638.

    • Search Google Scholar
  • Harjai, K., Khandwaha, R. K., Mittal, R., Yadav, V., Gupta, V., Sharma, S.: Effect of pH on production of virulence factors by biofilm cells of Pseudomonas aeruginosa. Folia Microbiol. 50, 99–102 (2005).

    Sharma S. , 'Effect of pH on production of virulence factors by biofilm cells of Pseudomonas aeruginosa ' (2005 ) 50 Folia Microbiol. : 99 -102.

    • Search Google Scholar
  • Sugimura, M., Maseda, H., Hanaki, H., Nakae, T.: Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52, 4141–4144 (2008).

    Nakae T. , 'Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa ' (2008 ) 52 Antimicrob. Agents Chemother. : 4141 -4144.

    • Search Google Scholar
  • Skindersoe, M. E., Alhede, M., Phipps, R., Yang, L., Jensen, P. O., Rasmussen, T. B., Bjarnsholt, T., Tolker-Nielsen, T., Høiby, N., Givskov, M.: Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52, 3648–3663 (2008).

    Givskov M. , 'Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa ' (2008 ) 52 Antimicrob. Agents Chemother. : 3648 -3663.

    • Search Google Scholar
  • Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S., Ciofu, O., Hoiby: Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35, 322–332 (2010).

    Ciofu O. , 'Hoiby: Antibiotic resistance of bacterial biofilms ' (2010 ) 35 Int. J. Antimicrob. Agents : 322 -332.

    • Search Google Scholar
  • Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. CLSI, Wayne, PA, 2006.

    '', in Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , (2006 ) -.

  • Černohoska, L., Votava, M.: Determination of minimal regrowth concentration (MRC) in clinical isolates of various biofilm-forming bacteria. Folia Microbiol. 49, 75–78 (2004).

    Votava M. , 'Determination of minimal regrowth concentration (MRC) in clinical isolates of various biofilm-forming bacteria ' (2004 ) 49 Folia Microbiol. : 75 -78.

    • Search Google Scholar
  • Song, W., Woo, L., Kim, J. S., Lee, K. M.: In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Internat. J. Antimicrob. Agents 21, 8–12 (2003).

    Lee K. M. , 'In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa ' (2003 ) 21 Internat. J. Antimicrob. Agents : 8 -12.

    • Search Google Scholar
  • Aaron, S. D., Ferris, W., Ramotar, K., Vandemheen, K., Chan, F., Saginur, R.: Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J. Clin. Microbiol. 40, 4172–4179 (2002).

    Saginur R. , 'Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis ' (2002 ) 40 J. Clin. Microbiol. : 4172 -4179.

    • Search Google Scholar
  • Kobayashi, H.: Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides. Am. J. Med. 99, 26S–30S (1995).

    Kobayashi H. , 'Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides ' (1995 ) 99 Am. J. Med. : 26S -30S.

    • Search Google Scholar
  • Mulet, X., Maciá, M. D., Mena, A., Juan, C., Pérez, J. L., Oliver, A.: Azithromycin in Pseudomonas aeruginosa biofilms: Bactericidal activity and selection of nfxB mutants. Antimicrob. Agents Chemother. 53, 1552–1560 (2009).

    Oliver A. , 'Azithromycin in Pseudomonas aeruginosa biofilms: Bactericidal activity and selection of nfxB mutants ' (2009 ) 53 Antimicrob. Agents Chemother. : 1552 -1560.

    • Search Google Scholar
  • Garey, K. W., Vo, Q. P., Lewis, R. E,, Saengcharoen, W., LaRocco, M. T., Tam, V. H.: Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn. Microbiol. Infect. Dis. 63, 81–86 (2009).

    Tam V. H. , 'Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin ' (2009 ) 63 Diagn. Microbiol. Infect. Dis. : 81 -86.

    • Search Google Scholar
  • Nagata, T., Mukae, H., Kadota, J., Hayashi, T., Fujii, T., Kuroki, M., Shirai, R., Yanagihara, K., Tomono, K., Koji, T., Kohno, S.: Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob. Agents Chemother. 48, 2251–2259 (2004).

    Kohno S. , 'Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model ' (2004 ) 48 Antimicrob. Agents Chemother. : 2251 -2259.

    • Search Google Scholar
  • Tanaka, G., Shigeta, M., Komatsuzawa, H., Sugai, M., Suginaka H., Usui, T.: Effect of clarithromycin on Pseudomonas aeruginosa biofilms. Chemotherapy 46, 36–42 (2002).

    Usui T. , 'Effect of clarithromycin on Pseudomonas aeruginosa biofilms ' (2002 ) 46 Chemotherapy : 36 -42.

    • Search Google Scholar
  • Saiman, L., Mehar, F., Niu, W. W., Neu, H. C., Shaw, K. J., Miller, G., Prince, A.: Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolates from CF patients, including transplant candidates. Clin. Infect. Dis. 23, 532–537 (1996).

    Prince A. , 'Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolates from CF patients, including transplant candidates ' (1996 ) 23 Clin. Infect. Dis. : 532 -537.

    • Search Google Scholar
  • Kandemir, O., Oztuna, V., Milcan, A., Bayramoglu, A., Celik, H. H., Bayarslan, C., Kaya, A.: Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis. Clin. Orthop. Relat. Res. 430, 171–175 (2005).

    Kaya A. , 'Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis ' (2005 ) 430 Clin. Orthop. Relat. Res. : 171 -175.

    • Search Google Scholar
  • Tré-Hardy, M., Vanderbist, F., Traore, H., Devleeschouwer, M. J.: In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int. J. Antimicrob Agents 31, 329–336 (2008).

    Devleeschouwer M. J. , 'In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures ' (2008 ) 31 Int. J. Antimicrob Agents : 329 -336.

    • Search Google Scholar
  • Saiman, L., Mehar, F., Niu, W. W., Neu, H. C., Shaw, K. J., Miller, G., Prince, A.: Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin. Infect. Dis. 23, 532–537 (1996).

    Prince A. , 'Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation ' (1996 ) 23 Clin. Infect. Dis. : 532 -537.

    • Search Google Scholar
  • Saiman, L., Chen, Y., Gabriel, P. S., Knirsch, C.: Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46, 1105–1107 (2002).

    Knirsch C. , 'Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis ' (2002 ) 46 Antimicrob. Agents Chemother. : 1105 -1107.

    • Search Google Scholar
  • Bui, K. Q., Banevicius, M. A., Nightingale, C. H., Quintiliani, R., Nicolau, D. P.: In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45, 57–62 (2000).

    Nicolau D. P. , 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa ' (2000 ) 45 J. Antimicrob. Chemother. : 57 -62.

    • Search Google Scholar
  • Giamarellos-Bourboulis, E. J., Antonopoulou, A., Raftogiannis, M., Koutoukas, P., Tsaganos T., Tziortzioti V., Panagou, C., Adamis, T., Giamarellou, H.: Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect. Dis. 6, 31 (2006).

    Giamarellou H. , 'Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa ' (2006 ) 6 BMC Infect. Dis. : 31 -.

    • Search Google Scholar
  • Shinkai, M., Lopez-Boado, Y. S., Rubin, B. K.: Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J. Antimicrob. Chemother. 59, 1096–1101 (2007).

    Rubin B. K. , 'Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin ' (2007 ) 59 J. Antimicrob. Chemother. : 1096 -1101.

    • Search Google Scholar
  • Furuhata, M., Iwamura, M., Baba, S., Inoue, M.: Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty. Int. J. Urol. 10, 228–230 (2003).

    Inoue M. , 'Combined effect of clarithromycin and imipenem/cilastatin against urinary biofilm infection after pyeloplasty ' (2003 ) 10 Int. J. Urol. : 228 -230.

    • Search Google Scholar

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
submission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 652 EUR / 812 USD
Subscription fee 2022 Online subsscription: 662 EUR / 832 USD
Print + online subscription: 740 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2021 3 0 0
Jul 2021 12 0 0
Aug 2021 3 0 0
Sep 2021 3 0 0
Oct 2021 6 0 0
Nov 2021 6 0 0
Dec 2021 0 0 0